Law360, New York (June 11, 2012, 4:52 PM ET) -- A Delaware judge on Monday kept alive a shareholder derivative suit seeking to hold Botox manufacturer Allergan Inc.'s board liable for a $600 million settlement with the U.S. Department of Justice over off-label Botox use, saying the dismissal of a related case shouldn’t count against investors.
At issue is a lawsuit targeting Allergan directors accused of overseeing illegal marketing of off-label Botox use for migraine headaches, cerebral palsy and other ailments, a practice that led to a settlement with the DOJ and a nine-figure blow to...
Allergan Can't Kick Investor Suit Over $600M Botox Settlement
To view the full article, take a free trial now.
